The blood group typing market is projected to reach USD 3.12 billion by 2021 from USD 1.95 billion in 2016, at a CAGR of 9.8 percent, estimates MarketsandMarkets. The increasing demand for blood and blood products, growing number of road accidents and trauma cases that necessitate blood transfusion, need for blood grouping during prenatal testing, and increasing usage of blood group typing in forensic sciences are the major factors fueling the growth of this market.
The consumables segment is expected to grow at the highest CAGR during the period, 2016–2021. The increase in blood donation rates and major surgical procedures (including organ transplant procedures) are the key factors driving the growth of this segment.
The PCR-based and microarray techniques segment is expected to grow at the highest CAGR. The large share and high growth of this segment can be attributed to the rising prevalence of chronic diseases and increasing R&D activities focused on understanding the molecular basis of blood and antibody-antigen interactions.
By test type, the market is classified into antibody screening, HLA typing, cross-matching tests, ABO blood tests, and antigen typing. The antibody screening segment is expected to grow at the highest CAGR. The growth of this market segment is primarily driven by the increasing prevalence of chronic disorders and growing demand for the early diagnosis of diseases.
Based on end user, the market is classified into hospitals, blood banks, clinical laboratories, and other end users. The hospitals end-user segment is expected to grow at the highest CAGR. This growth can be attributed to the increasing awareness on blood donations and their importance, rising number of blood donations, and growing requirement of blood in surgical treatments.
In 2016, North America accounted for the largest share of the market, followed by Europe. However, the market in Asia is expected to witness the highest CAGR, with the growth centered on China, Japan, and India in the coming years.